journal article·2024-01-03Open access

Potential of Radioactive Isotopes Production in DEMO for Commercial Use

Pavel Pereslavtsev, Christian Bachmann, Joelle Elbez-Uzan, Jin Hun Park

Applied Sciences· Volume 14· Issue 1

Abstract

There is widespread use of nuclear radiation for medical imagery and treatments. Worldwide, almost 40 million treatments are performed per year. There are also applications of radiation sources in other commercial fields, e.g., for weld inspection or steelmaking processes, in consumer products, in the food industry, and in agriculture. The large number of neutrons generated in a fusion reactor such as DEMO could potentially contribute to the production of the required radioactive isotopes. The associated commercial value of these isotopes could mitigate the capital investments and operating costs of a large fusion plant. The potential of producing various radioactive isotopes was studied from material pieces arranged inside a DEMO equatorial port plug. In this location, they are exposed to an intensive neutron spectrum suitable for a high isotope production rate. For this purpose, the full 3D geometry of one DEMO toroidal sector with an irradiation chamber in the equatorial port plug was modeled with an MCNP code to perform neutron transport simulations. Subsequent activation calculations provide detailed information on the quality and composition of the produced radioactive isotopes. The technical feasibility and the commercial potential of the production of various isotopes in the DEMO port are reported.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Fusion materials and technologies · Nuclear reactor physics and engineering · Nuclear Physics and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Karlsruhe Institute of Technology (KIT), Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen, 76344 Karlsruhe, Germany

EUROfusion Programme Management Unit, Fusion Technology Department—DEMO Central Team, Boltzmannstrasse 2, 85748 Garching, Germany

Funding

European Union via the Euratom Research and Training Programme

References (51)

Show source-provided references
1. Overview of the DEMO staged design approach in Europe10.1088/1741-4326/ab1178 ↗
2. DEMO tritium breeding performances with different in-vessel components configurations10.1016/j.fusengdes.2021.112319 ↗
3. Status and future development of Heating and Current Drive for the EU DEMO10.1016/j.fusengdes.2022.113159 ↗
4. (2023, December 25). Radioisotopes in Medicine, World Nuclear Association. Available online: https://www.world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx.
5. (2023, December 25). Nuclear Medicine Radioisotopes Market, Fact. MR. Available online: https://www.factmr.com/report/nuclear-medicine-radioisotopes-market.
6. Manual for Reactor Produced Radioisotopes (2023, December 25). IAEA-TECDOC-1340. International Atomic Energy Agency IAEA; January 2003. Available online: https://www-pub.iaea.org/MTCD/Publications/PDF/te_1340_web.pdf.
7. New strategies for a sustainable 99mTc supply to meet increasing medical demands: Promising solutions for current problems10.3389/fchem.2022.926258 ↗
8. National Research Council (2009). Medical Isotope Production without Highly Enriched Uranium, The National Academies Press.
9. Co-60 versus Ir-192 in HDR brachytherapy: Scientific and technological comparison
10. The Production of Medical Isotopes without Nuclear Reactors or Uranium Enrichment10.1080/08929882.2015.1037123 ↗
11. Williams, T.R. (2023, December 25). Starting a Brachytherapy Program in the United States, A Free International CME symposium, BrachyNext. Available online: https://www.aoic.net/elekta/elk1402archive/E204Williams.pdf.
12. Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: A comparison of Ir-192 versus Co-60 sources10.3802/jgo.2018.29.e86 ↗
13. Palladium-103 versus Iodine-125 for ophthalmic plaque radiotherapy10.1016/0360-3016(93)90459-9 ↗
14. (2023, December 25). Iodine-125 and Palladium-103 Low Dose Rate Brachytherapy Seeds Used for Localization of Non-Palpable Lesions. United States Nuclear Regulatory Commission; U.S.NRC, 24 May 2023, Available online: https://www.nrc.gov/materials/miau/med-use-toolkit/seed-localization.html.
15. (2023, December 25). Permanente Interstitielle Brachytherapie (Seed-Implantation) bei Lokal Begrenztem Prostatakarzinom, Ein Health Technology Assessment der Bundesärztekammer und der Kassenärztlichen Bundesvereinigung. Available online: https://www.bundesaerztekammer.de/fileadmin/user_upload/_old-files/downloads/70b.pdf.
16. Efficient 169Yb high-dose-rate brachytherapy source production using reactivation10.1002/mp.13563 ↗
17. Dupere, J.M., Munro, J.J., and Medich, D.C. (2021). Shielded high dose rate ocular brachytherapy using Yb-169. Phys. Med. Biol., 66.10.1088/1361-6560/ac02d6 ↗
18. Baker, P.S. (2023, December 25). Martha Gerrard, Iodine—125, Isotopes Information Center, ORNL-IIC-3, OAK RIDGE NATIONAL LABORATORY, Available online: https://www.osti.gov/servlets/purl/4706222.
19. (2023, December 25). Available online: https://www.perkinelmer.com/de/product/iodine-125-carrier-free-radionuclide-nez033001mc.
20. Perry, D.J., Patel, R.J., Yudelev, M., Keole, S.R., Frazier, A.J., Zuniga, C., and Dalmia, P. (2023, December 25). Cost Analysis of High vs. Low Activity Iodine-125 Seeds as Monotherapy for Permanent Prostate Brachytherapy. J. Clin. Onc. 2004. Available online: https://ascopubs.org/action/doSearch?field1=AllField&text1=Cost+analysis+of+high+vs.+low+activity+iodine-125+seeds+as+monotherapy+for+permanent+prostate+brachytherapy&Ppub=&Ppub=&AfterYear=&BeforeYear=.10.1200/jco.2004.22.90140.4717 ↗
21. (2023, December 25). ANSTO, Available online: https://www.ansto.gov.au/products/nuclear-medicine/product-list/pricing.
22. National Research Council (2008). Radiation Source Use and Replacement: Abbreviated Version, The National Academies Press.
23. In-Canal Assay of High Specific Activity 60Co at the Advanced Test Reactor10.1080/00295450.2021.1903299 ↗
24. Allen, H.F. (1964, January 13). Cobalt-60 Production at Savannah River, Reactor Technology Section Savannah River Plant. Proceedings of the American Nuclear Society (ANS) Process Radiation Meeting, Washington, DC, USA. DPSPU 64-30-16.
25. International Atomic Energy Agency (2008). Setting Up a Radiotherapy Programme: Clinical, Medical Physics, Radiation Protection and Safety Aspects, International Atomic Energy Agency. STI/PUB/1296.
26. Generator-Produced Yttrium-90 for Radioimmunotherapy
27. Radiation Safety Issues in Y-90 Microsphere Selective Hepatic Radioembolization Therapy: Possible Radiation Exposure from the Patients10.1007/s13139-010-0047-7 ↗
28. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK10.1080/13696998.2020.1731213 ↗
29. Ziessman, H.A., O’Malley, J.P.O., and Thrall, J.H. (2014). Nuclear Medicine, Elsevier. [4th ed.].
30. Samarium-153 Production using (n,γ) Reaction at TRIGA PUSPATI Research Reactor10.1063/5.0031608 ↗
31. Análisis coste-efectividad de samario-153 (Quadramet®) en el tratamiento del dolor en pacientes con cáncer de próstata y metastasis óseas10.1007/BF02712817 ↗
32. Economic and Clinical Net Benefits from the Use of Samarium Sm-153 Lexidronam Injection in the Treatment of Bone Metastases
33. Goldstein, N.E., and Morrison, R.S. (2013). Evidence-Based Practice in Palliative Medicine, Elsevier.
34. Knapp, F.F., Ambrose, K.R., Beets, A.L., Luo, H., McPherson, D.W., and Mirzadeh, D. (2023, December 25). Nuclear Medicine Program Progress Report for Quarter Ending, ORNL Report ORNL/TM-13107, 30 September 1995, Available online: https://www.osti.gov/servlets/purl/197822.10.2172/197822 ↗
35. (2023, December 25). Price List of Electromagnetically Separated Isotopes, ISE, Institute for Rare-Earth and Strategical Metals. Available online: https://en.institut-seltene-erden.de/unser-service-2/metall-preise/preise-fuer-stabile-isotope/.
36. Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer10.6004/jnccn.2022.7070 ↗
37. (2023, December 25). Appraisal Consultation Document—Lutetium-177 Vipivotide Tetraxetan for Treating PSMA-Positive Hormone-Relapsed Metastatic Prostate Cancer after 2 or More Treatments, Project: “Lu Vipivotide Tetraxetan for Treating PSMA-Positive Hormone-Relapsed Metastatic Prostate Cancer after 2 or More Therapies [ID3840]”. National Institute for Health and Care Exellence NICE. Available online: https://www.nice.org.uk/guidance/gid-ta10730/documents/129-2.
38. Lapi, S. (2007). Production and Evaluation of High Specific Activity 186Re: An Isotope for Radio Immunotherapy in Cancer Treatment. [Ph.D. Thesis, Simon Fraser University]. Available online: https://core.ac.uk/download/pdf/56372495.pdf.
39. (2023, December 25). Available online: https://www.flinnsci.com/beta-source-thallium-204/ap8797/.
40. Initial layout of DEMO buildings and configuration of the main plant systems10.1016/j.fusengdes.2018.02.101 ↗
41. Multi-functional Neutronics Calculation Methodology and Program for Nuclear Design and Radiation Safety Evaluation10.1080/15361055.2018.1475162 ↗
42. Consolidated design of the HCPB Breeding Blanket for the pre-Conceptual Design Phase of the EU DEMO and harmonization with the ITER HCPB TBM program
43. Pereslavtsev, P., Cortes, P., and Elbez-Uzan, J. (2023). Activation analyses of disposal options of irradiated Be12Ti. Appl. Sci., 13.10.3390/app13137534 ↗
44. Werner, C.J., Armstrong, J.C., Brown, F.B., Rising, M.E., McMath, G.E., Bull, J.S., Solomon, C., Hendricks, J.S., Casswell, L., and Sood, A. (2017). MCNP User’s Manual Code Version 6.2, Los Alamos National Laboratory. Tech. Rep. LA-UR-17-29981.
45. Fleming, M., Steiner, T., and Gilbert, M. (2023, December 25). The FISPACT II User Manual. CCFE-R(18)001, February 2018. Available online: https://fispact.ukaea.uk/_documentation/UKAEA-R18001.pdf.
46. The joint evaluated fission and fusion nuclear data library, JEFF-3.310.1140/epja/s10050-020-00141-9 ↗
47. Tokamak D-T neutron source models for different plasma physics confinement modes10.1016/j.fusengdes.2012.02.025 ↗
48. TENDL: Complete Nuclear Data Library for Innovative Nuclear Science and Technology10.1016/j.nds.2019.01.002 ↗
49. Activation and decay heat analysis of the European DEMO blanket concepts10.1016/j.fusengdes.2017.02.100 ↗
50. Comparative activation analyses for the HCPB breeding blanket in DEMO10.1016/j.fusengdes.2021.112338 ↗
51. Assessment of residual heat removal from activated breeding blanket segment during remote handling in DEMO10.1016/j.fusengdes.2021.112891 ↗